In aggregate, these studies have clearly demonstrated that pharmacological blockade of TGF-β signaling shifts the balance from bone breakdown to bone (re)generation, thereby inhibiting tumor-associated osteolysis. This evidence concerns the gene TGFB1 and neoplasm.